150 related articles for article (PubMed ID: 23846929)
21. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Santoni M; Conti A; De Giorgi U; Iacovelli R; Pantano F; Burattini L; Muzzonigro G; Berardi R; Santini D; Cascinu S
Int J Cancer; 2014 Aug; 135(4):763-73. PubMed ID: 24127298
[TBL] [Abstract][Full Text] [Related]
22. [Drug therapy for neuroendocrine tumours].
Tóth M
Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
[TBL] [Abstract][Full Text] [Related]
23. Pancreatic neuroendocrine tumors: targeting the molecular basis of disease.
Khagi S; Saif MW
Curr Opin Oncol; 2015 Jan; 27(1):38-43. PubMed ID: 25390554
[TBL] [Abstract][Full Text] [Related]
24. Targeted agents in treatment of neuroendocrine tumors of pancreas.
Karampelas IN; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):351-3. PubMed ID: 25076341
[TBL] [Abstract][Full Text] [Related]
25. [Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
Kato S
Nihon Rinsho; 2015 Aug; 73(8):1398-402. PubMed ID: 26281696
[TBL] [Abstract][Full Text] [Related]
26. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
[TBL] [Abstract][Full Text] [Related]
27. Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.
Ortolani S; Ciccarese C; Cingarlini S; Tortora G; Massari F
Future Oncol; 2015; 11(12):1809-28. PubMed ID: 26075448
[TBL] [Abstract][Full Text] [Related]
28. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial.
Neychev V; Steinberg SM; Cottle-Delisle C; Merkel R; Nilubol N; Yao J; Meltzer P; Pacak K; Marx S; Kebebew E
BMJ Open; 2015 May; 5(5):e008248. PubMed ID: 25991462
[TBL] [Abstract][Full Text] [Related]
29. [The newest perspectives on diagnostic methods and treatment of insulinoma].
Łabuzek K; Duda K; Cholewa H; Madej P; Okopińe B
Wiad Lek; 2014; 67(2 Pt 1):85-92. PubMed ID: 25764782
[TBL] [Abstract][Full Text] [Related]
30. Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors.
Yao JC; Phan AT; Hess K; Fogelman D; Jacobs C; Dagohoy C; Leary C; Xie K; Ng CS
Pancreas; 2015 Mar; 44(2):190-7. PubMed ID: 25426617
[TBL] [Abstract][Full Text] [Related]
31. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
Valle JW; Faivre S; Hubner RA; Grande E; Raymond E
Cancer Treat Rev; 2014 Dec; 40(10):1230-8. PubMed ID: 25283354
[TBL] [Abstract][Full Text] [Related]
32. Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition.
Passacantilli I; Capurso G; Archibugi L; Calabretta S; Caldarola S; Loreni F; Delle Fave G; Sette C
Oncotarget; 2014 Jul; 5(14):5381-91. PubMed ID: 25026292
[TBL] [Abstract][Full Text] [Related]
33. Everolimus Reduces (89)Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.
van Asselt SJ; Oosting SF; Brouwers AH; Bongaerts AH; de Jong JR; Lub-de Hooge MN; Oude Munnink TH; Fiebrich HB; Sluiter WJ; Links TP; Walenkamp AM; de Vries EG
J Nucl Med; 2014 Jul; 55(7):1087-92. PubMed ID: 24790218
[TBL] [Abstract][Full Text] [Related]
34. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
[TBL] [Abstract][Full Text] [Related]
35. [Targeted therapies, prognostic and predictive factors in endocrine oncology].
Hescot S; Baudin E; Borson-Chazot F; Lombès M
Ann Endocrinol (Paris); 2013 Oct; 74 Suppl 1():S13-22. PubMed ID: 24356287
[TBL] [Abstract][Full Text] [Related]
36. Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison.
Signorovitch J; Swallow E; Kantor E; Wang X; Klimovsky J; Haas T; Devine B; Metrakos P
Exp Hematol Oncol; 2013 Dec; 2(1):32. PubMed ID: 24314093
[TBL] [Abstract][Full Text] [Related]
37. Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.
Djukom C; Porro LJ; Mrazek A; Townsend CM; Hellmich MR; Chao C
Pancreas; 2014 Jan; 43(1):88-92. PubMed ID: 24263107
[TBL] [Abstract][Full Text] [Related]
38. Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma.
Fonseca PJ; Uriol E; Galván JA; Alvarez C; Pérez Q; Villanueva N; Berros JP; Izquierdo M; Viéitez JM
Case Rep Oncol; 2013; 6(2):441-9. PubMed ID: 24019785
[TBL] [Abstract][Full Text] [Related]
39. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.
Strosberg JR
Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
